In contrast, other studies have reported that PD-L1 expression is associated with poor prognosis in patients with NSCLC, gastric carcinoma, hepatocellular carcinoma and pancreatic cancer [30–33]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.